Abstract
The statins are the most important group of drugs for lipid-lowering therapy in the prevention of coronary heart disease. Greater reductions in LDL-cholesterol appear to be associated with greater benefits but the clinical efficacy and safety of statin treatment varies considerably from person to person because of a combination of phenotypic and genotypic factors. Pharmacogenetic studies have investigated the relationship between common genetic variants and the lipid responses to statin therapy and adverse events, and some candidate genes related to the pharmacodynamics and pharmacokinetics of different statins have been identified. Some of these genetic variants show a different frequency in different ethnic groups. This field of pharmacogenetic research is receiving considerable attention and many new findings have been reported recently. Pharmacogenetic and pharmacogenomic studies of statin therapy are likely to provide a better understanding of the effects of these drugs and to help with prediction of the most appropriate drug and dosage for each individual and whether the addition or substitution of other lipid modifying drugs may be necessary to achieve the most safe and effective prevention of coronary heart disease.
Keywords: Coronary heart disease, ethnic differences, HMG-CoA reductase inhibitors, LDL-cholesterol, pharmacogenetics
Current Pharmacogenomics and Personalized Medicine
Title: Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease
Volume: 7 Issue: 1
Author(s): M. Hu, V. W.L. Mak, T. T.W. Chu, M. M.Y. Waye and B. Tomlinson
Affiliation:
Keywords: Coronary heart disease, ethnic differences, HMG-CoA reductase inhibitors, LDL-cholesterol, pharmacogenetics
Abstract: The statins are the most important group of drugs for lipid-lowering therapy in the prevention of coronary heart disease. Greater reductions in LDL-cholesterol appear to be associated with greater benefits but the clinical efficacy and safety of statin treatment varies considerably from person to person because of a combination of phenotypic and genotypic factors. Pharmacogenetic studies have investigated the relationship between common genetic variants and the lipid responses to statin therapy and adverse events, and some candidate genes related to the pharmacodynamics and pharmacokinetics of different statins have been identified. Some of these genetic variants show a different frequency in different ethnic groups. This field of pharmacogenetic research is receiving considerable attention and many new findings have been reported recently. Pharmacogenetic and pharmacogenomic studies of statin therapy are likely to provide a better understanding of the effects of these drugs and to help with prediction of the most appropriate drug and dosage for each individual and whether the addition or substitution of other lipid modifying drugs may be necessary to achieve the most safe and effective prevention of coronary heart disease.
Export Options
About this article
Cite this article as:
Hu M., Mak W.L. V., Chu T.W. T., Waye M.Y. M. and Tomlinson B., Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease, Current Pharmacogenomics and Personalized Medicine 2009; 7 (1) . https://dx.doi.org/10.2174/187569209787582349
DOI https://dx.doi.org/10.2174/187569209787582349 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design In the Search of the Vulnerable Plaque: Current Diagnostic Techniques and Future Directions
Vascular Disease Prevention (Discontinued) Lipids and Non-Cardiac Vascular Disease: A Lecture Overview
Current Vascular Pharmacology A More Accurate Approach to Molecular Genetics Analysis in Vascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Mediterranean Diet and Low-grade Subclinical Inflammation: The Moli-sani Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Effect of Leptin on Vascular Nitric Oxide and Endothelial Function
Current Hypertension Reviews Editorial [Hot Topic: Tocotrienols: Potential Drug Targets for Cardiovascular, Cancer and Neurological Diseases (Executive Guest Editor: Dipak K. Das)]
Current Pharmaceutical Design Illuminating microRNA Transcription from the Epigenome
Current Genomics Immune Response to Native Lipoproteins Induces Visceral Obesity and Aortic Wall Injury in Rats: The Role of Testosterone
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Targets of Metformin in Cardioprotection: Beyond the Effects Mediated by AMPK
Current Pharmaceutical Design The Renal Epithelial Sodium Channel: Genetic Heterogeneity and Implications for the Treatment of High Blood Pressure
Current Pharmaceutical Design Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Controversies in Anticoagulant Therapy in Vitreo-Retinal Surgery
Current Pharmaceutical Design Lifestyle Choices and Endothelial Function: Risk and Relevance
Current Vascular Pharmacology Chagas Disease: Progress and New Perspectives
Current Medicinal Chemistry Heart Failure in Chronic Myocarditis: A Role for microRNAs?
Current Genomics Exploration of Different Methodologies for Synthesizing Biologically Important Benzothiazoles: An Overview
Current Organic Synthesis Subject Index To Volume 7
Current Pharmaceutical Design